Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes - PubMed (original) (raw)

. 1989 Feb 3;243(4891):660-3.

doi: 10.1126/science.2536954.

Affiliations

• PMID: 2536954
• DOI: 10.1126/science.2536954

Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes

S Seremetis et al. Science. 1989.

Abstract

The biological effects of ras oncogene activation in B cells were studied by using amphotropic retroviral vectors to introduce H- or N-ras oncogenes into human B lymphoblasts immortalized by Epstein-Barr virus. Expression of both H- and N-ras oncogenes led to malignant transformation of these cells, as shown by clonogenicity in semisolid media and tumorigenicity in immunodeficient mice. In addition, terminal differentiation into plasma cells was detectable as specific changes in morphology, immunoglobulin secretion, and cell surface antigen expression. This combined effect, promoting growth and differentiation in human lymphoblasts, represents a novel biological action of ras oncogenes and has implications for the pathogenesis of terminally differentiated B-lymphoid malignancies such as multiple myeloma.

PubMed Disclaimer

Similar articles

• Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity.
  Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, Forni G, Venuta S. Scala G, et al. J Exp Med. 1990 Jul 1;172(1):61-8. doi: 10.1084/jem.172.1.61. J Exp Med. 1990. PMID: 2162905 Free PMC article.
• Different biological effects of c-myc and H-ras oncogene expression in EBV-infected human lymphoblasts.
  Seremetis S, Inghirami G, Ferrero D, Lombardi L, Knowlest DM, Dotto GP, Dalla-Favera R. Seremetis S, et al. Curr Top Microbiol Immunol. 1988;141:290-7. doi: 10.1007/978-3-642-74006-0_39. Curr Top Microbiol Immunol. 1988. PMID: 2850896 No abstract available.
• [Studies on transforming functions of Epstein-Barr virus-specific proteins].
  Kinoshita T. Kinoshita T. Hokkaido Igaku Zasshi. 1990 Jul;65(4):362-75. Hokkaido Igaku Zasshi. 1990. PMID: 2172130 Japanese.
• Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
  Tanner JE, Alfieri C. Tanner JE, et al. Leuk Lymphoma. 1996 May;21(5-6):379-90. doi: 10.3109/10428199609093435. Leuk Lymphoma. 1996. PMID: 9172802 Review.
• Identification of EBV transforming genes by recombinant EBV technology.
  Izumi KM. Izumi KM. Semin Cancer Biol. 2001 Dec;11(6):407-14. doi: 10.1006/scbi.2001.0407. Semin Cancer Biol. 2001. PMID: 11669602 Review.

Cited by

• Multiple myeloma: increasing evidence for a multistep transformation process.
  Hallek M, Bergsagel PL, Anderson KC. Hallek M, et al. Blood. 1998 Jan 1;91(1):3-21. Blood. 1998. PMID: 9414264 Free PMC article. Review.
• Multistep tumorigenesis of multiple myeloma: its molecular delineation.
  Iida S, Ueda R. Iida S, et al. Int J Hematol. 2003 Apr;77(3):207-12. doi: 10.1007/BF02983776. Int J Hematol. 2003. PMID: 12731662 Review.
• RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas.
  Thiagalingam A, De Bustros A, Borges M, Jasti R, Compton D, Diamond L, Mabry M, Ball DW, Baylin SB, Nelkin BD. Thiagalingam A, et al. Mol Cell Biol. 1996 Oct;16(10):5335-45. doi: 10.1128/MCB.16.10.5335. Mol Cell Biol. 1996. PMID: 8816445 Free PMC article.
• Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
  Yang Y, Bolomsky A, Oellerich T, Chen P, Ceribelli M, Häupl B, Wright GW, Phelan JD, Huang DW, Lord JW, Van Winkle CK, Yu X, Wisniewski J, Wang JQ, Tosto FA, Beck E, Wilson K, McKnight C, Travers J, Klumpp-Thomas C, Smith GA, Pittaluga S, Maric I, Kazandjian D, Thomas CJ, Young RM. Yang Y, et al. Nat Commun. 2022 Sep 17;13(1):5469. doi: 10.1038/s41467-022-33142-x. Nat Commun. 2022. PMID: 36115844 Free PMC article.
• Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
  Jiang XN, Yu BH, Yan WH, Lee J, Zhou XY, Li XQ. Jiang XN, et al. Oncoimmunology. 2019 Nov 3;9(1):1683346. doi: 10.1080/2162402X.2019.1683346. eCollection 2020. Oncoimmunology. 2019. PMID: 32002294 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal